Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2017 | short review | Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017

Hematopoietic stem cell transplantation: up-date from ASH 2016

memo - Magazine of European Medical Oncology > Ausgabe 2/2017
MD Georg Hopfinger


Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e. g., with lenalidomide or rituximab.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017Zur Ausgabe